{
    "nct_id": "NCT03793543",
    "official_title": "Test-Retest Reproducibility of 18F-DCFPyL PET/CT in the Evaluation of Patients With Metastatic Prostate Cancer - an Interscan Variability and Intraobserver Agreement Study",
    "inclusion_criteria": "* Willing and able to provide written informed consent\n* History of histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology\n* Patients with metastatic castration-sensitive (CSPC) or castration-resistant prostate cancer (CRPC) with evidence of metastatic disease on conventional imaging with CT or bone scan.\n* Prior docetaxel-based chemotherapy is permitted\n* Documented metastatic prostate cancer progression as assessed by the treating oncologist with either one or both of the following and has not initiated a new therapy after determination of progression: Rising PSA over a minimum 1-week interval and/or radiographic progression in soft tissue and bone metastases (combination of bony and soft tissue metastases)\n* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection\n* Administered a radioisotope ≤5 physical half-lives prior to the date of study PET/CT\n* Administered IV X-ray contrast medium ≤24 hours prior to the date of study PET/CT\n* Administered oral contrast medium ≤120 hours prior to the date of study PET/CT\n* Condition or situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with patient's participation in the study",
    "miscellaneous_criteria": ""
}